Navigation Links
Health Enhancement Products, Inc. Secures Capital Increase To Fund Ongoing Bovine And Canine Studies For Licensing Opportunities

KEEGO HARBOR, Mich., July 17, 2014 /PRNewswire/ -- Health Enhancement Products, an innovative Michigan-based biotech firm, is pleased to announce that its primary lender has increased the company's credit facility to $6 million, making $1 million available immediately to expedite both canine and bovine validation studies currently underway in the United States and Canada.

"This new infusion of capital funding will allow us to expedite the promising work in a broader set of studies and potentially move from research to licensing discussions as early as this fall," said Andrew Dahl, President and CEO of Health Enhancement Products. "And, we view this latest investment and inquiries from equity capital investors as vote of confidence in our process and prospects."

With a pre-pilot experiment in dairy cows already successfully concluded, an expanded pilot program will assess the effectiveness of the Company's product as an intra-mammary treatment and as an oral alternative, among other forms of administration. HEPI's primary business is investigating bioactive compounds extracted from algal cultures through research facilities in Montreal, Canada and Tulare County, California.

"The bovine pilot program involves larger groups of dairy cows and refinements to our approach," states Dr. Amy Steffek, Director of R&D. "We've already authorized our contract research organization (CRO) to proceed, and the pilot program will be initiated the week of July 21. The plan is to have pilot program preliminary results by the end of August or early September and share that information with our animal health collaboration partner."

The pilot program is a continuing research and validation effort directed at immune response in addressing bovine mastitis, a condition that affects milk production and costs American dairy producers almost $3 billion in milking losses annually. Bovine mastitis is a global problem, affecting at any one time up to 10% of the world's 244 million cows.

Concurrently, the Company is expanding the previously announced canine study to include refined samples and a direct challenge model that pits the company's bioactive compounds against glucosamine and chondroitin – the most popular active ingredients in the canine joint health supplement market.

"Glucosamine and chondroitin are the most common supplement ingredients available to consumers for pet health. The market is large and stable, even in the current economic climate," states Dahl. "We'd like to offer dog owners a viable alternative that can be more cost-effectively and safely administered for months, if not years, without any worries and also provide the additional benefit of a healthy immune system response."

Like their human owners, dogs and other animals serving as family pets and companions in the USA and around the world experience loss of joint health due to advancing age, weight, and breed type. Joint health issues are predicted to affect nearly 1 in 5 dogs, and the canine joint health supplement market currently generates roughly $300 million in annual sales in the U.S. alone.

Results from the glucosamine-chondroitin challenge experiment are expected in mid-to-late September, at which point Company principals hope to  be in a position enter discussions with potential joint-venture partners and licensees to position specific product applications for market introduction.

About Health Enhancement Products, Inc.

Health Enhancement Products, Inc. (OTCQB: HEPI) is a Michigan-based biotech company engaged in the investigation of the health benefits of bioactive compounds derived from its proprietary algal cultures, and the development of natural bioactive compounds for use as dietary supplements and food ingredients, as well as potential candidates for future medicinal and pharmaceutical applications in humans and animals, focused on autoimmune modulation.

Safe Harbor Statement

Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the timing of completion of a trial, actual future clinical trial results being different than the results the company has obtained to date, and the company's ability to secure funding. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and those actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, whether as a result of new information or otherwise.

SOURCE Health Enhancement Products, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Cryoport and DHL Partner to Provide Cryogenic Logistics Solutions for Life Sciences and Healthcare Clients
2. USDM Life Sciences’ Grant Hodgkins Elected to GS1 Healthcare Leadership Team
3. inVentiv Health Initiates Refinancing Transactions To Fund Continued Growth
4. Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy
5. Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography
6. EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System
7. Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership
8. New Years Resolution: Give Pets the Gift of Top-Notch Health Care
9. Organovo Announces Collaboration with National Institutes of Health
10. Telemedicine and M-Health Convergence: Market Shares, Strategies, and Forecasts, Worldwide, 2013 to 2019
11. MiMedx to Present at 32nd Annual J.P. Morgan Healthcare Conference
Post Your Comments:
(Date:12/1/2015)... , Dec. 1, 2015 Researchers at the ... Institute for Brain Research at MIT have engineered changes ... cut down on "off-target" editing errors. The refined technique ... use of genome editing. Science , ... three of the approximately 1,400 amino acids that make ...
(Date:12/1/2015)... , Dec. 1, 2015 Frost & ... program. This program addresses ways companies can innovate ... --> ... --> ... healthcare, as well as the disrupting factors altering ...
(Date:12/1/2015)... Minn. , Dec. 1, 2015  The Minnesota ... recipient of the 2015 Tekne Award in the Small ... at the Minneapolis Convention ... have played a significant role in developing new technologies ... living around the world. Clostridium difficile ...
(Date:12/1/2015)... , Dec. 1, 2015  CardioCell LLC, a ... stem cells for cardiovascular indications, intends to proceed ... based on recommendations from a Heart Failure Advisory ... Scientific Advisory Board members . In a ... Phase IIa safety and efficacy data from CardioCell,s ...
Breaking Biology Technology:
(Date:11/19/2015)... MOUNTAIN VIEW, Calif. , Nov. 19, 2015 /PRNewswire/ ... authentication market, Frost & Sullivan recognizes BIO-key with the ... Strategy Leadership. Each year, Frost & Sullivan presents this ... comprehensive product line catering to the needs of the ... which the product line meets and expands on customer ...
(Date:11/18/2015)... 18, 2015  As new scientific discoveries deepen our ... other healthcare providers face challenges in better using that ... In addition, as more children continue to survive pediatric ... and old age. John M. Maris, M.D ... of Philadelphia (CHOP) . --> John ...
(Date:11/17/2015)... November 17, 2015 Paris ... --> Paris from 17 th ... the biometrics innovation leader, has invented the first combined scanner ... the same scanning surface. Until now two different scanners were ... scanner can capture both on the same surface. This ...
Breaking Biology News(10 mins):